Holen Sie sich die Stockscreener-App
6.62
2.00%
0.13
Handel nachbörslich:
6.62
Schlusskurs vom Vortag:
$6.49
Offen:
$6.34
24-Stunden-Volumen:
236.38K
Relative Volume:
1.52
Marktkapitalisierung:
$377.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.86M
KGV:
-5.5167
EPS:
-1.2
Netto-Cashflow:
$-58.82M
1W Leistung:
+2.00%
1M Leistung:
+9.78%
6M Leistung:
+103.69%
1J Leistung:
+28.54%
1-Tages-Spanne:
$6.00
$6.73
1-Wochen-Bereich:
$6.00
$7.22
52-Wochen-Spanne:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Vergleichen Sie DSGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
6.62 | 369.59M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
How to integrate Design Therapeutics Inc. into portfolio analysis tools2025 Big Picture & Fast Gain Swing Alerts - newser.com
How Design Therapeutics Inc. stock reacts to global recession fearsTrade Analysis Summary & Safe Capital Allocation Plans - newser.com
Does Design Therapeutics Inc. fit your quant trading modelIndex Update & Risk Controlled Daily Trade Plans - newser.com
Is it time to cut losses on Design Therapeutics Inc.Analyst Downgrade & Risk Controlled Daily Plans - newser.com
Published on: 2025-10-10 09:52:08 - newser.com
Leading vs lagging indicators on Design Therapeutics Inc. performanceJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com
Is Design Therapeutics Inc. a candidate for recovery playJuly 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com
Design Therapeutics Inc. stock volume spike explainedJuly 2025 Short Interest & AI Optimized Trade Strategies - newser.com
Why Design Therapeutics Inc. stock is in analyst buy zone2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Design Therapeutics (NASDAQ:DSGN) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Published on: 2025-10-09 02:15:05 - newser.com
Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025 - Yahoo Finance
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ong - PharmiWeb.com
Is Design Therapeutics Inc a good long term investmentInstitutional Buying Trends & Low Entry Investment Plans - earlytimes.in
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ongoing Clinical Trials, Market Dynamics, Patent AnalysisResearchAndMarkets.com - Business Wire
Design Therapeutics Inc. recovery potential after sell offFed Meeting & Real-Time Chart Pattern Alerts - newser.com
Should you hold or exit Design Therapeutics Inc. now2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Top chart patterns to watch in Design Therapeutics Inc.2025 Price Targets & Free Verified High Yield Trade Plans - newser.com
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5 - 富途牛牛
Analyzing Design Therapeutics Inc. with multi timeframe chartsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
Risk adjusted return profile for Design Therapeutics Inc. analyzedEarnings Performance Report & Stepwise Entry and Exit Trade Signals - newser.com
Why Design Therapeutics Inc. stock is a must watch in 2025Trade Signal Summary & Smart Swing Trading Alerts - newser.com
Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design - Business Wire
Vector Science & Therapeutics Appoints Tabitha Hendren as Director, Engineering and Design - PR Newswire Canada
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Bausch + Lomb, Santen Pharmaceutical, and Trefoil Therapeutics, Actively Shaping the Competitive Landscape - 24matins.uk
Design Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Low Cost Stock Picks - earlytimes.in
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):